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The class II transactivator (CIITA) is a transcriptional
co-activator regulating the constitutive and interferon-
-inducible expression of class II major histocompatibil-
ity complex (MHC) and related genes. Promoter remod-
eling occurs following CIITA induction, suggesting the
involvement of chromatin remodeling factors. Tran-
scription of numerous genes requires the histone acetyl-
transferase (HAT) activities of CREB-binding protein
(CBP), p300, and/or p300/CBP-associated factor (pCAF).
These co-activators cooperate with CIITA and are hy-
pothesized to promote class II major histocompatibility
complex transcription through their HAT activity. To
directly test this, we used HAT-defective CBP and pCAF.
We demonstrate that cooperation between CIITA and
CBP is independent of CBP HAT activity. Further, al-
though pCAF enhances CIITA-mediated transcription,
pCAF HAT domain dependence appears contingent
upon the concentration of available CIITA. When HAT-
defective CBP and pCAF are both present, cooperativity
with CIITA is maintained. Consistent with a recent re-
port, we show that nuclear localization of CIITA is en-
hanced by lysine 144, an in vitro target of pCAF-medi-
ated HAT. Yet we find that neither mutation of lysine
144 nor deletion of residues 132–209 affects transcrip-
tional cooperation with CBP or pCAF. Thus, acetylation
of this residue may not be the primary mechanism for
pCAF/CBP cooperation with CIITA. In conclusion, the
HAT activities of the co-activators are not necessary for
cooperation with CIITA.
Expression of class II major histocompatibility complex
(MHC)1 molecules is a critical feature of the normal immune
response playing a central role in inflammatory, T cell-medi-
ated, and humoral responses through presentation of exoge-
nous, processed antigens to CD4 T cells. Constitutive class II
MHC expression is tissue-specific and restricted to B cells,
monocytes/macrophages, and dendritic cells (reviewed in Refs.
1 and 2), although inducible class II MHC is seen on most class
II negative tissues/cells in response to interferon-. Both con-
stitutive and inducible class II MHC expression is globally
regulated at the transcriptional level by the transcriptional
co-activator class II transactivator (CIITA) (reviewed in Ref. 3).
All known class II MHC-related genes containing the classical
W, X, and Y promoter motifs are regulated by CIITA (4–8).
The molecular mechanism by which CIITA activates and
regulates the transcription of class II MHC genes has been an
area of intense interest. CIITA is regulated by up to four
promoters that allow for the observed patterns of constitutive
and inducible expression (9, 10). CIITA is expressed in both the
cytoplasm and the nucleus (11). Nuclear import of CIITA de-
pends upon the presence of a defined nuclear localization se-
quence (NLS) (11), requires GTP-binding by CIITA (12), and is
contingent upon leucine-rich repeats (LRRs) in the carboxyl-
terminal portion of CIITA (3, 13).2 Recent studies have shown
that CIITA self-associates through its LRR, sequences within
its GTP-binding region, and the amino terminus (15–17), al-
though how this impacts nuclear translocation and transcrip-
tional activation by CIITA is not well understood. Once inside
the nucleus, CIITA interacts with both the required class II
MHC transcription factors (RFX, CREB, and NF-Y) and basal
transcription components (TFIIB, TBP, and TAFs) (18–23). In
vivo footprinting studies of the human leukocyte antigen DR 
gene (HLA-DRA) and invariant chain promoters in non-B cells
revealed that these promoters are usually “closed” in the ab-
sence of CIITA (24, 25) with little if any detectable binding by
X and Y box binding factors. The observation that promoters
can be “opened” by CIITA is indicative of chromatin remodeling
that could be mediated directly by CIITA or through recruit-
ment of chromatin remodeling co-activators that may rely upon
histone acetyltransferase (HAT) activity. Some examples in-
clude CREB-binding protein (CBP), p300, and p300/CBP-asso-
ciated factor (pCAF). Interestingly, recent work shows that
histones H3 and H4 are acetylated at the HLA-DRA promoter
in the presence of CIITA (26).
CBP interacts and synergizes with CIITA in the activation of
class II MHC transcription in transient transfection experi-
ments through an interaction with the amino terminus of CI-
ITA (21, 27). This interaction has recently been mapped and
shown to occur between residues 68 and 103 of CIITA (28).
When overexpressed, CIITA sequesters CBP (thus down-regu-
lating other CBP-dependent genes) (28), and a dominant neg-
ative form of CBP can inhibit class II MHC expression (21).
CIITA also interacts and cooperates with p300 (29) and pCAF
(30). Although these observations suggest that CBP and other
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co-activators are important for class II MHC transcription,
another critical issue is whether the HAT domains of CBP/
pCAF are required for the observed effects. Likewise, it is not
clear whether acetylation of CIITA affects its transactivator
function. The answers to these issues would greatly affect our
view of how CIITA transactivates its target promoters.
In this report, we demonstrate that the HAT activity of CBP
is not required for the synergistic cooperation between CIITA
and CBP. Further we demonstrate that the CBP-associated
factor pCAF, which also possesses a HAT domain, similarly
cooperates with CIITA and can also function in a HAT-inde-
pendent fashion. Complementing these findings, we also show
that a lysine residue that can be acetylated is not required for
cooperativity with pCAF. These findings have important impli-
cations regarding the mode of action of CIITA.
MATERIALS AND METHODS
Tissue Culture Cells and Conditions—The African green monkey
kidney cell line COS-7 was maintained in RPMI 1640 medium supple-
mented with 10% fetal calf serum and streptomycin-penicillin. All cells
were grown at 37 °C with 5% CO2.
Plasmids—The plasmid expression vectors encoding CIITA, 132–
209, CBP, pCAF, and the DRA300Luc reporter have been described
previously (5, 11, 31, 32). pCAFHATA (579–608) and pCAFHATB
(609–624) lack HAT activity (32) and fail to enhance p300/EBNA2-
mediated LMP1 transcription (33). CBPHAT() was produced by intro-
ducing two amino acid substitutions at residues 1690 and 1691 of
wild-type CBP by Quick ChangeTM (Stratagene) mutagenesis. This
mutation has been previously shown to completely abolish histone
acetyltransferase activity, resulting in a CBP molecule that fails to
activate a CRE-containing promoter (34), and demonstrates diminished
transcription activation in cooperation with the Epstein-Barr virus Z
protein (35).
Transfection and Promoter Assays—Cells (2  104 to 2  105) were
plated in 6-well tissue culture plates 18–24 h prior to transfection of
plasmid DNAs using FuGene6 (Roche Molecular Biochemicals) trans-
fection reagent per the manufacturers instructions. Following transfec-
tion (24–48 h), the cells were lysed in 1 reporter lysis buffer (Pro-
mega), and luciferase assays were performed as described previously
(36).
Immunofluorescence Microscopy—Immunofluorescent staining of
transiently transfected COS-7 cells was performed as described previ-
ously (16). Briefly, 8  104 cells were grown overnight and transfected
with 1.5 g of DNA using the FuGene6 transfection reagent (Roche
Molecular Biochemicals). Following fixation with 40% acetone in phos-
phate-buffered saline, the cells were blocked with 1% bovine serum
albumin in phosphate-buffered saline and stained with anti-FLAG M5
(Sigma) and goat anti-mouse IgG-fluorescein isothiocyanate. Photomi-
crographs were acquired using Scion Series 7 video capture hardware
and an Olympus BX40 fluorescence microscope.
RESULTS
Cooperation between CIITA and CBP and/or pCAF Does Not
Require CBP or pCAF Histone Acetyltransferase Activity—
Transcriptional cooperation of the co-activators CBP and pCAF
with CIITA has been previously reported (21, 27, 30), implicat-
ing the importance of HAT activity in transactivation by CI-
ITA. A variety of transfection methods using differing ratios of
co-activator to CIITA have been reported (21, 27). To reduce the
risk of missing the effects of cooperation by overexpressing
CIITA, we transfected various quantities of CIITA with a fixed
quantity of the DRA reporter (Fig. 1A). In COS-7 cells, activa-
tion of DRA transcription was maximal with 100 ng of trans-
fected CIITA DNA. Significant transcriptional activation oc-
curs with 20 ng as well. Transfecting 1 g of CIITA DNA gives
a level of activation similar to 20 ng, suggesting some form of
inhibition at this high concentration. The relationship observed
between the amount of DNA transfected and the degree of
activation is consistent for a variety of cell lines (data not
shown). A previous analysis of the dose response of class II
MHC transcription to CIITA demonstrated a linear relation-
ship in various tissues (37). This disagreement is likely due to
the high transfection efficiency (60–90%) using the FuGene
reagent in this report as compared with the other transfection
method. For the purposes of this study only the 20- and 100-ng
quantities of CIITA are used.
To investigate the importance of CBP HAT activity in tran-
scriptional activation of class II MHC genes by CIITA, we
tested the ability of a HAT-defective form of CBP to cooperate
with CIITA in transient transfection experiments. This same
FIG. 1. Activation of the DRA promoter by CIITA does not
require the HAT domain of either CBP or pCAF. A, dose response
of the DRA300Luc reporter with transfected CIITA. COS-7 cells were
co-transfected with the indicated amounts of CIITA DNA and 1 g of
DRA reporter. Sufficient empty vector (pcDNA3) was added to bring the
total quantity of transfected DNA to 2 g. Luciferase activity was
normalized to the 20-ng CIITA transfectant (100%), which displayed
10–15-fold activation compared with vector alone. B and C, effect of
equivalent concentrations of co-activators on transcriptional activation
mediated by 0.1 g of CIITA. COS-7 cells were co-transfected with the
indicated amounts of CIITA or vector alone and CBP or a CBP HAT-
defective mutant (B) and pCAF or pCAF HAT-deficient mutants (C). D
and E, effect of overexpressed CBP (D) or pCAF (E) and the respective
HAT-defective mutants on activation by 20 ng of CIITA. COS-7 cells
were co-transfected with equal amounts of the indicated constructs. The
values are shown as the mean percentages of relative luciferase activ-
ity  S.E. for three experiments, each of which was repeated in tripli-
cate. pREP4, pCMV5, and pCI-neo are empty vector controls for CIITA,
CBP, and pCAF respectively.
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construct has been previously tested as being HAT-deficient in
other systems (34, 35). The HAT-defective form of CBP and two
HAT-defective forms of pCAF (32) enhanced CIITA activity as
well as wild-type CBP and pCAF, respectively (Fig. 1, B and C).
Co-transfection of 0.1 g of CIITA with equivalent concentra-
tions of pCAF or CBP constructs reveals HAT-independent
cooperation of CIITA with either CBP or pCAF (Fig. 1, B and
C). When CBP is overexpressed (50-fold relative to CIITA; Fig.
1D), only a small difference is observed between cooperation
with wild-type and HAT-defective CBP. However, under simi-
lar conditions, wild-type pCAF enhances the activity of CIITA,
whereas the two pCAF HAT-defective mutants (pCAFHATA
and pCAFHATB) display a reduced, but still detectable,
capacity to enhance CIITA-mediated transcription (Fig. 1E).
Taken together these data suggest that cooperation of CIITA
with CBP is mostly HAT-independent. Cooperation of pCAF
with CIITA is partially HAT-dependent when reporter activa-
tion by CIITA is suboptimal (20 ng of transfected CIITA plas-
mid) (Fig. 1E). When CIITA activity is optimal (0.1 g), coop-
eration occurs but is HAT-independent. No cooperation is
observed when an excess of CIITA plasmid (1 g) is used (data
not shown).
CBP often recruits pCAF, and it is very likely that CBP and
pCAF act together (38, 39). Thus, we further examined the role
of the HAT domains of CBP and pCAF using equivalent
amounts (0.1 g) of the DNAs in co-transfection experiments.
Under these conditions, CBP and pCAF together gave a greater
than 5-fold enhancement of HLA-DRA activation compared
with CIITA alone (Fig. 2A). No significant change in enhance-
ment is observed when the HAT-defective forms of CBP, pCAF,
or both are used. Similar results are obtained using 50-fold
overexpression of the co-activators relative to CIITA (Fig. 2B).
This cooperation between CIITA/CBP/pCAF, maintained by
HAT-defective co-activators, strongly suggests that the HAT
activities of CBP and pCAF are not required for transcriptional
cooperativity with CIITA.
Cooperation between CIITA and CBP or pCAF Is Independ-
ent of Residues 132–209 of CIITA—Our previous analysis has
shown that residues 132–209 of CIITA are not required for
activation of DR transcription (5). However, it has been re-
cently shown that mutation of lysines 141 and 144 or lysines
156 and 159 to arginine within this region has an effect on
nuclear localization, consistent with the existence of a putative
bipartite NLS acetylated by both CBP and pCAF (30). Fig. 3A
shows the sequence of CIITA from 132 to 209, the positions of
the bipartite NLS, and lysines in this region. The CIITA dele-
tion mutant 132–209 activates DRA transcription and is com-
parable with wild-type CIITA using 1.0 g of DNA (Fig. 3B).
This is consistent with our previous report using this mutant at
a high concentration (5). At 0.1 and 0.02 g, the transactivation
ability of 132–209 is substantially lower than wild type. Re-
duced transactivation by 132–209 is consistent with a defect
in nuclear localization (Fig. 3C) and thus the presence of the
bipartite NLS. This paradoxical defect of nuclear localization
and successful activation of DR transcription at a higher con-
centration of CIITA has been recently observed using LRR
mutants of CIITA.2 These LRR mutations reduce the import
rate of CIITA without diminishing its ability to activate tran-
scription once nuclear CIITA levels are adequate, which is
achieved with a higher concentration of CIITA. Contrary to the
earlier observation that deleting residues 132–209 of CIITA
does not abrogate transactivator function, a recent paper sug-
gests that acetylation of CIITA at residues 141 and 144 could
be instrumental to CBP/pCAF-enhanced transcription by
CIITA (30). More specifically, nuclear localization was shown to
be dependent upon lysines 141 and 144 and was positively
affected by the HAT activity of pCAF. However, the contribu-
tion of HAT activity to transcriptional activation and the role of
each individual lysine residue was not investigated. If CBP
and/or pCAF acetylation of CIITA at lysines 141 and/or 144
reflects the mechanism of cooperativity, CBP and pCAF should
fail to cooperate with CIITA132–209. To examine this possi-
bility, we transfected cells with different forms of CIITA and
either CBP, CBPHAT(), pCAF, or pCAFHATA/B under con-
ditions where the HAT domain of pCAF is necessary for full
cooperativity. In these experiments the level of transactivation
by 132–209 is reduced to 30% of wild type. However, cooper-
ation with CIITA, as measured by the capacity of CBP or pCAF
to enhance transactivation, is preserved (Fig. 3, D and E).
Furthermore, this cooperation mirrors that seen with wild-type
CIITA with respect to a partial dependence on the pCAF HAT
domain (Fig. 3D) and independence from CBP HAT activity
(Fig. 3E). Also, like wild type, when equivalent amounts (0.1
g) of CIITA and pCAF (or CBP) are used, the dependence on
FIG. 2. Co-expression of CIITA with
both CBP and pCAF reveals no re-
quirement for CBP or pCAF HAT do-
mains. A, effect of CBP and pCAF co-
expression on activation of DRA reporter
by 0.1 g of CIITA. COS-7 cells were co-
transfected with 0.1 g each of vector
alone or CIITA and the indicated co-acti-
vator constructs along with the DRA re-
porter. B, effect of CBP and pCAF co-
expression on activation of DRA reporter
by 20 ng of CIITA. COS-7 cells were co-
transfected with CIITA or vector alone, 1
g of the indicated co-activator constructs
and 500 ng of DRA reporter. The values
shown represent the mean data from
three experiments. See Fig. 1 legend for
additional details.
CBP/pCAF HAT Domain-independent Transactivation by CIITA 38717
pCAF HAT activity disappears (data not shown). These obser-
vations demonstrate that deleting residues 132–209 did not
affect cooperation with CBP or pCAF. The slight dependence on
the pCAF HAT domain is still present despite the absence of
the lysine(s) in the bipartite NLS, suggesting that this modest
enhancement does not require acetylation in this region of
CIITA. The following experiment using site-specific mutagen-
esis was performed to address this issue further.
Acetylation at CIITA Residue 144 Is Not Necessary for Tran-
scriptional Activation or Cooperation with CBP and pCAF—A
previous study demonstrated that lysine 144 of CIITA is acety-
lated by pCAF and suggested that either lysines 144 and/or 141
are acetylated by CBP (30). The same report also shows that
mutation of both of these residues to arginine had a negative
effect on pCAF-enhanced CIITA nuclear localization. However,
the transactivation function of K144R and K141R individually
has not been tested prior to this report. To this end, single point
mutagenesis was performed. Single point mutation of lysine
141 to arginine (K141R) has no effect on activity (Fig. 4B) or
localization (Fig. 4C, middle panel). K144R displays no defect
in transactivation assays, even when as little as 20 ng of DNA
is transfected (Fig. 4B). Remarkably, K144R also displayed
nearly complete cytoplasmic localization (Fig. 4B), consistent
with the prior report. This demonstrates that the localization
effects previously tested result from mutation of Lys144, not
Lys141 or the combination of both mutations, and suggests that
on a per molecule basis, K144R is likely more active than
wild-type CIITA, because K144R exhibits defective nuclear
accumulation (Fig. 4C). This represents a rare gain-of-function
mutation of CIITA.
To assess the effect of the K144R mutation on cooperation
with CBP and pCAF, several experiments were performed us-
ing this mutant. If acetylation of K144 is responsible for coop-
eration between pCAF (or CBP) and CIITA, a failure of coop-
eration would be expected. Using both the 50-fold over-
expression and “equivalent” expression systems, pCAF cooper-
ated with K144R (Fig. 5). The ability of CBP and CBPHAT()
to cooperate with K144R was essentially identical using the
50-fold overexpression conditions (data not shown). These data
demonstrate that acetylation of CIITA at lysine 144 by pCAF is
not necessary for cooperation with pCAF. The same is true of
CBP (data not shown).
DISCUSSION
The ability of CIITA to activate class II MHC transcription
can be enhanced by the presence of the co-activators CBP (21,
27), pCAF (30), or p300 (29). Similar observations have been
made for CBP using class I MHC reporters consistent with the
role of CIITA in class I MHC transcription (8, 40). Acetylation
of lysine 144 of CIITA by pCAF and lysines 141 and/or 144 by
CBP, which comprise a bipartite nuclear localization sequence,
has been demonstrated recently to play a role in enhancing the
nuclear import of CIITA (30). These previous studies implicate
the importance of HAT activities in promoting the transcrip-
tion of class II MHC genes. Here we directly test an aspect of
this hypothesis. This report explores the implied requirement
for HAT activity of CBP and pCAF for enhancing CIITA trans-
activation of class II MHC genes and finds that the HAT
domains of CBP and pCAF are frequently not required. Fur-
ther, a lysine residue within 132–209 that is acetylated by the
pCAF HAT is dispensable for cooperativity with the co-activa-
tors. This particular residue is important for nuclear accumu-
lation, as described previously (30).
This report confirms previous findings that CBP and pCAF
cooperate with CIITA; however, we find that this cooperation is
completely independent of HAT activity contributed by CBP.
Further, this cooperation can also be independent of pCAF
HAT activity depending on the conditions. Although some de-
pendence for pCAF HAT activity was observed when pCAF was
transfected in excess of CIITA, this was not observed when
equivalent amounts of either wild-type CBP or HAT-defective
CBP and CIITA were co-expressed. HAT independence is also
observed when HAT-defective pCAF and CBP are used in com-
bination. HAT-independent cooperation between co-activators
and other transcription factors has been well documented (32,
41–43) and is thought to occur through either recruitment of
additional co-factors or directly through the non-HAT domains
of the co-activators themselves. We consistently observe a lack
of HAT dependence for CBP cooperation with CIITA at various
concentrations of CIITA, using different amounts of transfected
DNA and using different expression vectors (Fig. 1 and data
not shown). As the concentration of CIITA increases, we ob-
serve a decreased enhancement with CBP (data not shown). We
interpret this to indicate a decreasing reliance upon CBP, and
perhaps co-activators in general, as the amount of available
CIITA increases. These results are consistent with the hypoth-
FIG. 3. Residues 132–209 of CIITA that contain a bipartite NLS
are not necessary for cooperation with CBP or pCAF. A, protein
sequence of wild-type human CIITA between residues 131 and 210. The
depicted region is missing from the CIITA deletion construct 132–209.
Lysines comprising the bipartite NLS are shown in bold type. Also
indicated are the lysine residues that are acetylated by pCAF (*) and
likely acetylated by CBP () (see text) (30). B, dose response of the
DRA300Luc reporter with transfected CIITA or 132–209. COS-7 cells
were co-transfected with the indicated amounts of CIITA or 132–209
DNA and 1 g of DRA reporter. Sufficient empty vector (pcDNA3) was
added to bring the total quantity of transfected DNA to 2 g. Luciferase
activity was normalized and expressed as in Fig. 1A. C, nuclear local-
ization of CIITA and 132–209. D and E, effect of co-activators and the
respective HAT-defective mutants on activation by 132–209. COS-7
cells were co-transfected with 20 ng of 132–209 or vector alone and 1
g of pCAF (D) or CBP (E).
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esis that at some defined concentration of CIITA, CBP is less
important for activation of class II transcription.
Cooperative activation of class II MHC by CIITA and pCAF
or CBP does not require sequences between 132 and 209 of
CIITA, despite the presence of pCAF/CBP acetylation sites in
this region. In a similar fashion, point mutation of the lysines
identified as acetylation targets fail to impair the activity of
CIITA or its ability to cooperate with co-activators. Together,
these observations suggest that although CIITA interacts and
cooperates with CBP and pCAF, the HAT activities of these
factors, even in combination (Fig. 2), are not an absolute re-
quirement for cooperative transactivation. In addition, the pu-
tative acetylation sites for these HATs in CIITA are also not
required for cooperation with pCAF.
These data are consistent with several interpretations: 1) An
essential HAT activity is supplied by another co-activator (e.g.
p300, GCN5, SRC-1, or TAFII250). The interaction of CIITA
with p300 has been reported (29), and indirect association with
TAFII250 has been suggested (23). In light of this report, the
role of the HAT activities of these factors in class II MHC
transcription should be investigated. 2) CIITA may possess its
own HAT activity. This possibility is supported by a recent
report that CIITA has acetyltransferase activity (44). 3) Other
features of the co-activators, independent of the HATs are
important. 4) HAT recruitment is important for acetylation of
other factors involved in class II MHC transcription (e.g. NF-Y;
Ref. 45), and this requirement is sensitive to available CIITA.
(5) Lastly, the assay systems currently employed to address the
role of HATs in class II MHC transcription may be inadequate.
The characterization of K144R is intriguing because al-
though its nuclear import is clearly impaired, its transactiva-
tion function is not (Fig. 4C). The nuclear localization of 132–
FIG. 4. Mutation of pCAF/CBP-
acetylated lysine 144 reveals a gain of
CIITA function with reduced nuclear
import. A, protein sequence of CIITA be-
tween residues 131 and 210. Lysines 141
and 144, which are targeted by the HAT
domains of pCAF and/or CBP (see text
and Fig. 3A), were mutated to arginines.
B, dose response of the DRA300Luc re-
porter with transfected CIITA or the sin-
gle-point mutants K141R and K144R.
COS-7 cells were co-transfected with the
indicated amounts of CIITA, K141R, or
K144R and 1 g of DRA reporter, as in
Fig. 1A. C, nuclear localization of CIITA,
K141R, and K144R.
FIG. 5. Cooperation of CIITA with
CBP and pCAF does not require ly-
sine residue 144. A, effect of pCAF or a
pCAF HAT-defective mutant on activa-
tion by 20 ng of the K144R mutant. COS-7
cells were co-transfected with 20 ng of
vector alone or K144R and 1 g of the
indicated co-activator constructs along
with 0.5 g of DRA reporter. B, effect of
pCAF or a pCAF HAT-defective mutant
on activation by 0.1 g of K144R. COS-7
cells were co-transfected with 0.1 g of
each of the indicated constructs along
with 0.5 g of DRA reporter.
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209 is also reduced, although this mutant has impaired
function using smaller amounts of transfected DNA (Fig. 3).
We have recently observed that decreases in the rate of CIITA
import exhibited by the LRR mutants correlate with an acti-
vation profile similar to that seen for 132–209 over a range of
0.1–1.0 g, in that the transactivation function is comparable
with the wild-type CIITA at a high concentration but is reduced
at a lower concentration.2 A likely explanation is that for 132–
209 and the LRR mutants, although functional, fewer of these
molecules accumulate in the nucleus. K144R exhibits a differ-
ent pattern: defective nuclear localization, yet transactivation
comparable with wild type. These observations suggest that
K144R is potentially more active on a per molecule basis than
wild type and may represent the first described gain-of-func-
tion CIITA mutant. Combined with a previous report indicat-
ing that lysine 144 is an acetylation site, we speculate that this
acetylation may have the unexpected result of reducing trans-
activation function on a per molecule basis. Clearly, more de-
tailed analysis is necessary to explore this intriguing
possibility.
In summary, our observations regarding co-activator func-
tion and CIITA are consistent with reports demonstrating
HAT-independent cooperation in other systems (32, 41) and
changes in co-activator cooperativity with altered levels of
transcription factor expression (14). Interestingly, transcrip-
tional activation by CIITA shows a requirement for the HAT
domain of pCAF only when CIITA is less abundant. It seems
clear that acetylation by pCAF promotes nuclear import of
CIITA (30), and this requires Lys144. Once inside the nucleus,
CIITA causes specific gene activation assisted by CBP and
pCAF. The function of CBP is HAT-independent, whereas the
role of pCAF can be HAT-dependent. As CIITA availability
increases, even the HAT activity of pCAF is no longer required.
Co-activator involvement in the CIITA/class II MHC system is
thus complex and underscores the need for a more complete
understanding of the role of HATs in CIITA-mediated tran-
scriptional control.
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